Sales of its blockbuster asthma drug Dupixent rose 20.3% to 3.48 billion euros, compared with 3.44 billion euros expected on average by analysts. Sales of Beyfortus, a new treatment to protect ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU ...

The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine ...

WEDNESDAY, April 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.

In 2024, Dupixent sales came in at $14.1 billion, which was an increase of 22% from 2023. Dupixent’s trajectory contributed heavily to Sanofi’s strong quarterly performance.

April 21, 2025 – The FDA just approved the popular drug Dupixent for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and ...

All growth rates mentioned below are on a year-on-year basis and at CER. In Immunology, Dupixent generated sales of €3.48 billion in the quarter, up 20.3% year over year, driven by strong ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...